Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
Journal of Neuro-Oncology, 03/05/2012
Urgoiti GBR et al. – The data suggest extended adjuvant temozolomide (i.e., more than six cycles) should be considered in patients with newly diagnosed glioblastoma multiforme (GBM).
The authors conducted a population-based analysis to determine if extended adjuvant TMZ treatment (i.e., more than six cycles) confers a survival advantage as compared to the standard six cycles for newly diagnosed GBM patients.
Patient data was collected from the Alberta Cancer Registry and patient charts.
Progression free-and overall survival was determined in patients receiving six cycles of adjuvant TMZ and compared with that of patients receiving more than six cycles.
Patients in whom adjuvant chemotherapy was stopped at cycle six experienced a median survival of 16.5months, whereas, those who received more than six cycles survived for 24.6months (p=0.031).
Extended adjuvant therapy was not associated with increased toxicity.
In multivariate analysis, adjuvant monthly Temozolomide for more than six cycles was an independent prognostic factor for both progression free-and overall survival.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.